Atlas Trials

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Clinical trial NCT02971839 · TERMINATED

Trial details

NCT number
NCT02971839
Sponsor
Vertex Pharmaceuticals Incorporated
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2016-12-01
Primary completion
2017-08-01
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.